Focused On-demand Library for GDNF family receptor alpha-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

GDNF receptor beta; Neurturin receptor alpha; RET ligand 2; TGF-beta-related neurotrophic factor receptor 2

Alternative UPACC:

O00451; E9PD47; O15316; O15328; Q58J92; Q6GTR9; Q7Z5C2


GDNF family receptor alpha-2, also known as GDNF receptor beta or Neurturin receptor alpha, plays a crucial role in the nervous system's development and maintenance. It acts as a receptor for neurturin, facilitating the autophosphorylation and activation of the RET receptor, and mediates GDNF signaling, essential for neuronal survival and differentiation. This protein also participates in the phosphorylation of STAT3, a key signaling molecule in various cellular processes.

Therapeutic significance:

Understanding the role of GDNF family receptor alpha-2 could open doors to potential therapeutic strategies. Its involvement in critical signaling pathways for neuronal development and maintenance highlights its potential as a target for treating neurodegenerative diseases and injuries affecting the nervous system.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.